Progress DNDI-6148, an oxaborole compound, through clinical development for the treatment of leishmaniasis
current phase of drug development
updated 1 Mar 2022
DNDi’s screening of Anacor’s library of drug compounds from the oxaborole class, followed by focused medicinal chemistry efforts, led to the discovery of a number of analogues showing efficacy in animal models of Chagas disease, leishmaniasis, and sleeping sickness.
One of these compounds, acoziborole, is currently progressing through Phase II/III trials for sleeping sickness. An analogue compound, DNDI-6148, emerged as a promising lead candidate and was shown to be effective against Leishmania strains in various in vitro and in vivo studies. In late 2018, the decision was made to progress DNDI-6148 to a first-in-human Phase I single ascending dose study in healthy volunteers.
News & resources
- 28 October 2021 - DNDI-6148: A novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis, Journal of Medicinal Chemistry
- 29 June 2021 - Identification of resistance determinants for a promising antileishmanial oxaborole series, Microorganisms
Get our latest news, personal stories, research articles, and job opportunities.